Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Study
Pyrotinib combined with metronomic vinorelbine showed promising efficacy and an acceptable safety profile in HER2-positive advanced breast cancer patients after trastuzumab failure.
Authors
- Yehui Shi (ORCID: https://orcid.org/0000-0001-9649-7119)
- Zhongsheng Tong (ORCID: https://orcid.org/0000-0001-8060-5699)
- Wenjing Meng
- Lan Zhang (ORCID: https://orcid.org/0000-0002-7572-1035)
- Xiaodong Liu (ORCID: https://orcid.org/0000-0002-6879-990X)
- Jie Zhang (ORCID: https://orcid.org/0000-0002-1397-5224)
- Xuming Wang (ORCID: https://orcid.org/0000-0002-2266-8816)
- Shufen Li (ORCID: https://orcid.org/0000-0002-7338-2770)
- Chunfang Hao
- Li Zhang (ORCID: https://orcid.org/0000-0002-4702-9658)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- National Clinical Research (US)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2024-08-09
- DOI
- https://doi.org/10.4143/crt.2024.340
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Jiangsu Hengrui Medicine